creat bluematrix
bgne buy meet manag highlight
messag met bgne cfo howard liang discuss compani
progress toward becom fulli integr global biotech compani well
expect regard pipelin updat takeaway zanubrutinib
phase data waldenstrom macroglobulinemia wm remain track could
potenti valid superior claim imbruvica ph trial cll
remain track data potenti earli file patient pend reg
discuss tislelizumab strategi focus broad access sever strateg option
global zanubrutinib phase trial relapsed/refractori treatment-na patient
waldenstrom macroglobulinemia wm track top-lin data releas
year could potenti valid superior imbruvica recal trial
first head-to-head comparison zanubrutinib zanu imbruvica design
show superior zanu term complet remiss cr good partial
respons rate vgpr patient mutat wm
patient management note median follow-up time unblind like around
month import consider given respons btk inhibitor
wm tend deepen time manag remain confid zanu potenti product
profil given zanubrutinib achiev vgpr global phase trial
imbruvica demonstr vgpr pivot phase ii studi
similar follow-up time prior unblind random portion bgne plan present
result cohort trial guid present eha icml cohort
singl arm side-studi difficult treat wm patient wild-
type accord bgne imbruvica limit activ patient major
respons rate pivot studi zanu demonstr major respons
rate wt patient phase management continu guid first
nda file zanubrutinib us earli expect potenti label
wm includ previous untreat relapsed/refractori patient case
imbruvica
high confid success probabl global zanubrutinib phase trial
cll enrol well interim result guid recal bgne
current enrol two global phase trial zanu cll random trial
treatment-na patient vs bendamustin rituxan interim result guid
random trial relapsed/refractori cll patient compar zanu
vs imbruvica orr endpoint stepwis non-inferior superior
statist analys management point unlik azn acalabrutinib calquenc
evalu phase elev cll tn studi top-lin result guid
bgne line cll trial could potenti support use zanu front-lin
cll patient azn elev cll tn evalu calquenc line cll patient
compar chlorambucil gazyva chlorambucil gazyva treatment candid
constitut line cll opportun azn design trial similar fashion
imbruvica initi trial older patient cll manag remain
confid zanu success chanc demonstr superior vs br particular
context recent publish result allianc trial woyach et al nejm dec
demonstr superior imbruvica vs br similar patient second
random phase trial compar zanu /w imbrivica r/r cll patient like complet
shortli follow line cll trial accord manag addit bgne plan
initi addit studi evalu zanu combin agent includ
del cohort treatment-na cll patient could potenti support earli nda
fill upsid scenario pend regulatori discuss upsid scenario
bgne note might potenti posit evalu acceler approv
page analyst certif import disclosur
pathway zanu us pend regulatori discuss follow data disclosur
del patient recal februari bgne complet enrol treatment-
naiv cll patient carri delet up-siz cohort patient initi
newli diagnos cll patient carri del poor
prognosi imbruvica venclexta obtain acceler fda-approv
treatment-na del cll patient base singl arm open label studi demonstr
overal respons rate patient respect
phase zanu updat guid present eha june addit
data wt cohort phase wm studi see bgne also
present first full result mo follow-up pivot phase ii china trial r/r cll
updat pivot phase ii china mcl studi previous
present see comment recal two nda base
trial accept nmpa chines regulatori agenc august octob
prioriti review statu besid global phase studi evalu zanubrutinib
mcl data previous present wm data lastli iwwm annual
meet see comment phase studi evalu zanubrutinib
gazyva cll data previous updat eha icml well
tislelizumab ex-asia right like return bgne celg/bmi merger close
accord management celg invest program sinc origin
licens agreement pivot trial on-going global bgne note like
compani receiv tislelizumab ex-asia right back celg/bmi
addit termin fee would avoid potenti intern depriorit
tislelizumab also market opdivo compli regul
prevent anti-competit practic importantli would minim impact
oper aspect global tislelizumab develop program sinc bgne alreadi
oper run on-going registr trial management plan clarifi
tislelizumab global strategi later year near-term termin fee
off-set outstand celg reimburs cost longer term bgne could either re-partn
asset develop much bigger global develop platform
tislelizumab china approv guidanc top-lin data global pivot liver
urotheli cancer studi maintain bgne previous submit nda
tislelizumab china treatment relapsed/refractori r/r classic hodgkin lymphoma
chl august prioriti review us management complet enrol
patient global phase ii pivot studi liver cancer top-lin result
present management anticip fill discuss us fda later
year context bgne note potenti impact mrk fail
studi regulatori prospect like limit depend degre full
dataset present see preview planner
bgne also plan present pivot phase ii data urotheli cancer china trial file
nda china year addit five phase lung cancer trial complet
patient enrol potenti initi data start read
tislelizumab commerci strategi china like focus provid
broad access drug pend approv accord management context think
nation reimburs price competitor anti inhibitor china could potenti
provid interest refer point price bgne tislelizumab summer
note previous link four monoclon antibodi opdivo keytruda
toripalimab sintilimab recent obtaind regulatori
approv china believ like four approv inhibitor includ
price negoti drug candid list ndrl summer final reimburs
price could potenti provid refer point tislelizumab bgne price china
bgne manag note commerci strategi like focu access
rather price goal take advantag china oncolog sale forc
current second largest among domest intern competitor
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic beigen ltd
next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori beigen ltd bgne
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
